LEGAL DISCLAIMER

IMPORTANT NOTICE
This presentation has been prepared by Vessi Medical Ltd. (the “Company”) solely for informational purposes. The information contained herein has been prepared to assist prospective investors in making their own evaluation of the Company and does not purport to be complete or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data set forth in this information. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. The Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any errors omissions in, this presentation. This presentation includes certain statements and estimates provided by the Company with respect to the projected future performance of the Company. Such statements, estimates and projections reflect various assumptions by management concerning possible anticipated results, which assumptions may or may not be correct. No representations are made as to the accuracy of such statements, estimates or projections. This presentation may contain statements that are not historical facts, referred to as “forward looking statements.” The Company’s actual future results may differ materially from those suggested by such statements. No assurance can be given that future events will occur or that projections will be achieved. Past performance is not a reliable indication of future performance. This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of the Company’s securities, or an offer to sell, or a solicitation of an offer to buy, the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. Prospective investors should not construe the contents of this presentation as business, legal, tax, investment or other advice. Each prospective investor should make his, her or its own inquiries and consult his, her or its own advisors as to the appropriateness and desirability of an investment in the Company and as to business, legal, tax and related matters concerning an investment in the Company.

An investment in the Company shall be allowed only to such number and category of investors in accordance with applicable laws and regulations and pursuant to a predetermined process. Accordingly, detailed information in connection with the investment shall be revealed and delivered only to a limited number of qualifying investors as provided by law.
Vessi uses surface cryotherapy to treat superficial bladder cancer, a $1.2 billion market.
COMPANY HIGHLIGHTS

- Changing the standard of care for superficial bladder cancer
- Patent-pending, bladder-specific cryotherapy technology
- First-line, in-office, minimally invasive treatment alternative to surgery

- Successful proof of concept in animals; Design ready for first human trials
- Backed by the Trendlines Group, a leading Israeli early stage healthcare investor, and the Israeli innovation authority
- Highly-experienced leadership team with proven track record
NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) GREATLY AFFECTS QUALITY OF LIFE

- Mental health impact\(^1\)
- Sexual dysfunction\(^1\)
- Pain & blood in urine\(^2\)
- Frequent need to urinate\(^2\)
- Urinary leakage\(^3\)

3. Non-muscle invasive bladder cancer is associated with decreased physical health-related quality of life: Wayne Brisbane
Bladder cancer is the fourth most common cancer in men\textsuperscript{1}

75% of all bladder cancers are NMIBC\textsuperscript{1}

2 million suffer globally from NMIBC\textsuperscript{2}

300,000 new cases every year\textsuperscript{1}

\textbf{NMIBC:} Surface cancer on the inside lining of the bladder

THE STANDARD OF CARE HAS NUMEROUS LIMITATIONS

**TURBT**: UP TO 80% NMIBC RECURRENCE

Recurrences due to
- Missed tumors
- Dispersion of cancer cells
- Incomplete resection

Result in
Multiple-rePEAT procedures

*TURBT*: bleeding, perforation

- Bladder muscle damage
- Hospitalization
- Reduced QoL

*TransUrethral Resection of Bladder Tumor

4. AUA Guideline for the Management of Nonmuscle Invasive Bladder Cancer 2007 Update (Feb 12, 2014)
5. Ozer K et al. Bladder injury secondary to obturator reflex is more common with plasmakinetic TUR than monopolar TURBT. Cent Euro J Urol 2015; 68: 284-288
FREEZES THE TUMOR. ELIMINATES THE CANCER.

• Successfully ablates unwanted tissue
• Eliminates risk of dispersed cancer cells
• No damage to bladder muscle
• Reduces complications
• Improves quality of life
EASY-TO-USE, NOVEL CRYOTHERAPY SYSTEM TO TREAT NMIBC

1. Vessi’s cryo catheter device inserted into bladder via cystoscope (endoscope)

2. Using standard optics, physician identifies treatment area

3. Physician releases cryo spray; cryo process (ablation) begins
Balances the ideal cooling temperature & pressure for targeted cell destruction while protecting the bladder. Patent-pending national phase and PCT.

Designed for the specific environment of the bladder.

Intuitive “same style” TURBT procedure for quick & easy user adoption.

**UNIQUE CRYO SPRAY TECHNOLOGY FOR HOLLOW ORGANS**
VESSI'S EASY IN-OFFICE TREATMENT: WIN-WIN FOR ALL

PATIENT

- LESS INVASIVE TREATMENT
- SAFER & SIMPLER
- ENHANCED QUALITY OF LIFE

PHYSICIAN

- IMPROVED TREATMENT OPTION
- PATIENT RETENTION
- INCREASED REVENUE STREAM

HEALTH CARE SYSTEM

- REDUCED COSTS
- IN-OFFICE PROCEDURE
PROOF OF CONCEPT

SUCCESSFUL PROOF OF CONCEPT IN ANIMALS WITH ALPHA PRODUCT DEMONSTRATED SAFETY & EFFICACY

- Effective ablation of treated tissue
- Excellent visualization of treated tissue (during and between ablation cycles)
- Bladder muscle remained unharmed

Cryo activation inside the bladder (as observed via cystoscope)

Ablated transitional epithelium & lamina propria

Unharmed muscle

Unharmed Muscle

Treated Tissue
“Surface cryotherapy is a potential paradigm shift in the treatment of superficial bladder cancer”

“Tissue response to the cryo spray can be seen in real-time, allowing us to assess destruction of the tissue”

“Visualization is excellent at all procedure stages and is not affected by the cryo spray”

“Histology results demonstrated efficacy of tissue destruction and safety since there was no bladder perforation or bleeding. This gives us confidence to proceed to first-in-human trials”
Cryo activation inside the bladder (as observed via cystoscope): Before, During, After

Ready for Human Trials
REGULATORY AND REIMBURSEMENT

USA REIMBURSEMENT IN PLACE

REGULATORY

• 510(k) class II expected (pre-submission process is suggested)

• CE class IIA device expected (according to European MDD)
A NEW HOPE IN NMIBC TREATMENT
APPROACH TO MARKET

TARGET MARKET
$1.2 BILLION

• Start with low-grade papillary tumors; $850 million approximated world-wide market

• Continue with high-grade and carcinoma in-situ NMIBC

Low-grade papillary tumors: ~70% of NMIBC¹

¹ AUA Guideline for the Management of Nonmuscle Invasive Bladder Cancer 2007 Update (Feb 12, 2014)

DISPOSABLE-BASED BUSINESS MODEL

• End-user price $1,200/disposable catheter

• Expected COGS $55 (mass-production)

• Additional revenue from console unit
Teleflex closes $1B NeoTract buy

OCTOBER 3, 2017 BY BRAD PERRIELLO — LEAVE A COMMENT

Boston Scientific Announces Agreement
To Acquire NxThera

Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia

Mar 21, 2018

BTG plc acquires Galil Medical, a leader in cryoablation

London 06 May 2016

21 NOVEMBER 2019 NEWS

Boston Scientific to acquire BTG in $4.2bn deal

Planned Q1 2019
{reg. approval needed}
Vessi is raising funds in order to demonstrate the technology in humans.
HIGHLY EXPERIENCED LEADERSHIP; PROVEN TRACK RECORD

Eyal Kochavi, Founder & CEO
Seasoned medical device manager with vast cryotherapy experience; prior positions with Motus GI, Galil Medical, Given Imaging; MSc, MBA, Technion Israel institute of Technology

Moti Simchon, Cryogenics Advisor
45 years' experience in pneumatics, fine mechanics, and cryogenics; prior position at Raphael Defense Systems

Doron Birger, Business Advisor
Former President and CEO, Elron (NASDAQ-ELRN); former Chairman Given Imaging (NASDAQ-GIVN); chairman and board member of numerous medical device companies

Prof. Gilad E. Amiel, Scientific Advisor
Chairman, Department of Urology, Rambam, Israel; adjunct Associate Professor of Urology, Baylor College, Houston, Texas; former President of the American Association for Cancer Education (AACE)

Prof. Yair Lotan, Scientific Advisor
Professor of Urology, Chief of Urologic Oncology, and holder of Professorship in Urology at UT Southwestern Medical Center; Medical Director of the Urology Clinic at Parkland Health and Hospital System
WHY INVEST IN VESSI MEDICAL?

- Unique, patent-pending, bladder-specific cryotherapy technology
- In-office, easy-to-use, minimally invasive treatment for NMIBC
- Successful proof of concept in animals, Design ready for First human trials
- Billion dollar NMIBC market
- Highly-experienced leadership team with proven track record
NEW HOPE IN BLADDER CANCER TREATMENT

Eyal Kochavi | CEO & Founder
eyal@vessimed.com
+972.52.523.5454

THANK YOU